Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cholera vaccine inactivated oral - Valneva

Drug Profile

Cholera vaccine inactivated oral - Valneva

Alternative Names: Vibrio cholerae and enterotoxigenic Escherichia coli vaccine - Crucell/sanofi-aventis; Dukoral; SBL Cholera Vaccine; WC/rBS; whole cell/recombinant B subunit cholera vaccine

Latest Information Update: 22 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SBL Vaccin AB
  • Developer Crucell; Valneva
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera; Escherichia coli infections

Most Recent Events

  • 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
  • 26 Jan 2016 IC 51 sub-licensed to GlaxoSmithKline in Germany
  • 23 Jul 2015 Inactivated oral cholera vaccine (Dukoral®) licensed to PaxVax for commercialisation in Italy, Spain and Portugal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top